ST. JOSEPH, Mich., March 7 /PRNewswire-FirstCall/ -- GeneGo, Inc., the leading systems biology tools company, announced today that its systems pharmacology product MetaDrug 2.0(TM) won the “Best in Show” product award at the CHI’s Molecular Medicine Marketplace (MMM) conference held in San Francisco last week. MetaDrug was chosen a winner among six other systems biology products by conference attendee votes. MetaDrug helps to predict indications, off target effects and human toxicity for novel small molecules compounds using systems level chemoinformatics tools and manually annotated knowledge base of compound-target interactions, diseases, toxic categories, drug and endogenous metabolic pathways and signaling interactions.
“We are very pleased with winning this award,” said Julie Bryant, GeneGo’s VP of Business development. “MMM is the most important trade show in our field and is attended by the top experts in systems biology, translational medicine and medicinal chemistry, whose opinion matters a great deal for us. This year, we took a considerable risk with MetaDrug, our second product, as it competed with the latest versions of flagship suites launched by our competitors at MMM. We are glad this risk paid off.”
“MetaDrug is a unique platform,” said Tatiana Nikolskaya, GeneGo’s CSO and President. “There are probably a hundred commercial and open source products for pathway and network analysis of biological data but virtually nothing for chemistry. Prediction of biological effects for small molecules is a tough problem. Structure-centered chemoinformatics tools do not help explain systems level effects like disease indications; and simple assembly of ligand- receptor interactions databases are not sufficient either. We spent almost three years developing patent-pending MetaDrug technology and we are very glad it is appreciated by the market. We are also grateful to NIH which supported MetaDrug with SBIR grants.”
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 4.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug2.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company’s web site at www.genego.com
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
